TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23902931

Group type: EXPERIMENTAL
Intervention: Brief intervention based on the Information‐Motivation‐Behavioural Skills (IMB) Model
Number of subjects: 1196

Group type: COMPARATOR
Intervention: Health education leaflet on sensible drinking
Number of subjects: 1196
Study: 21269547

Group type: EXPERIMENTAL
Intervention: 4 g EPH (egg-protein hydrolysate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 8 g EPH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 12 g EPH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4 g EPH with 2 g MP (milk protein)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 4 g MP
Number of subjects: 20
Study: 19418394

Group type: EXPERIMENTAL
Intervention: Digital image cytometry (DICM)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard biopsy protocol
Number of subjects: 164
Study: 16952781

Group type: EXPERIMENTAL
Intervention: Oxypurinol 600 mg/day for 1 month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14766718

Group type: EXPERIMENTAL
Intervention: Practice based continuing medical education with coaching on performance review and implementation of new care processes.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 44
Study: 11149473

Group type: EXPERIMENTAL
Intervention: Single iv infusion of 90 mg of pamidronate (group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: First infusion of 90 mg of pamidronate followed by 30 mg every 3 months (group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Calcium alone (group C)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both pamidronate regimens
Number of subjects: 32
Study: 9298517

Group type: EXPERIMENTAL
Intervention: 12 micrograms/kg nicotine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 8136741

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day of ambisome
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 3119786

Group type: EXPERIMENTAL
Intervention: Recombinant DNA‐produced gamma‐interferon (3, 30, 300, 1,000, or 3,000 micrograms/m2) administered intravenously over two hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant DNA‐produced gamma‐interferon (1,000 micrograms/m2) administered continuously over 24 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant DNA‐produced gamma‐interferon (1,000 micrograms/m2) administered daily either by two or 24 hour infusion for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant DNA‐produced gamma‐interferon
Number of subjects: 30
Study: 29451869

Group type: EXPERIMENTAL
Intervention: Alternating inflatable head pad
Number of subjects: 120

Group type: COMPARATOR
Intervention: Gel head pad (Control)
Number of subjects: 120
Study: 27531486

Group type: EXPERIMENTAL
Intervention: Mecobalamin tablets and glutathione injection during chemotherapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Glutathione injection only
Number of subjects: 94
Study: 24067881

Group type: EXPERIMENTAL
Intervention: Adalimumab therapy (160 mg followed by 80 mg)
Number of subjects: 963
Study: 22430274

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/d for 4 weeks followed by 2 weeks off treatment (schedule 4/2)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Sunitinib 37.5 mg/d on the continuous daily dosing (CDD) schedule
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Schedule 4/2
Number of subjects: 292

Group type: COMPARATOR
Intervention: Schedule 4/2 and CDD
Number of subjects: 292
Study: 20521015

Group type: EXPERIMENTAL
Intervention: Dysglycemic group (n=39)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Euglycemic group (n=31)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Reference vessel diameter (RVD)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stent area (SA)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stent volume (SV)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG)
Number of subjects: 70
Study: 18674743

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 1820
Study: 17707978

Group type: EXPERIMENTAL
Intervention: Phytostanol supplementation (1.6 g of free phytostanol equivalents as phytostanol ester, 2.7 g stanol esters)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14521249

Group type: EXPERIMENTAL
Intervention: Community intervention program delivered via local mass media and reinforced by indigenous volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison condition (control group)
Number of subjects: 0
Study: 10960756

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V (self-etching primer) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2V after K-etchant (40% phosphoric acid gel) pre-conditioning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (artificially prepared wedge-shaped lesions)
Number of subjects: 0
Study: 8982778

Group type: EXPERIMENTAL
Intervention: Peptide immunotherapy (IPC-1 and IPC-2, 250 micrograms, s.c. injections weekly for 4 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Peptide immunotherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 1451645

Group type: EXPERIMENTAL
Intervention: L-carnitine (30 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6431573

Group type: EXPERIMENTAL
Intervention: 0.5-mg oral dose of brotizolam
Number of subjects: 12
Study: 30887937

Group type: EXPERIMENTAL
Intervention: Green banana biomass (40 g) (RS: approximately 4·5 g)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 113
Study: 30086659

Group type: EXPERIMENTAL
Intervention: Group-based cognitive behavioral therapy (CBT) stress management program
Number of subjects: 362

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 362
Study: 26968269

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol alone (0.03 ml/kg/dose)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nebulised salbutamol with ipratropium bromide (250 ug/dose)
Number of subjects: 200
Study: 25224654

Group type: EXPERIMENTAL
Intervention: Steroid-eluting bioabsorbable implant placed in the office after ESS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Steroid-eluting bioabsorbable implant
Number of subjects: 20
Study: 22785573

Group type: EXPERIMENTAL
Intervention: Amlodipine combination regimen
Number of subjects: 263

Group type: COMPARATOR
Intervention: Increased ARB regimen
Number of subjects: 263
Study: 19288975

Group type: EXPERIMENTAL
Intervention: Riluzole (100-200 mg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17694684

Group type: EXPERIMENTAL
Intervention: Supplemental magnesium infusion (2 g after induction of anesthesia, then 8 g upon arrival in ICU until 24 hr)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group (no magnesium infusion)
Number of subjects: 345
Study: 16979991

Group type: EXPERIMENTAL
Intervention: MMF 1.35 +/- 0.23 g/d (group 1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: MMF 2 g/d (group 2)
Number of subjects: 55
Study: 12553918

Group type: EXPERIMENTAL
Intervention: Temporal bisection task
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Numerical bisection task
Number of subjects: 3
Study: 10563400

Group type: EXPERIMENTAL
Intervention: 1 g meropenem tds
Number of subjects: 83

Group type: COMPARATOR
Intervention: amikacin 15 mg/kg single dose daily plus ceftazidime 2 g tds
Number of subjects: 83
Study: 8894145

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (120 mg for Group I, 180 mg for Group II, 240 mg for Group III) with daily infusions of either 30 mg or 60 mg for 2 years.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (60 mg infusions) for 2 years.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium treatment.
Number of subjects: 71
Study: 1829841

Group type: EXPERIMENTAL
Intervention: Stenting (Palmaz stent)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Angioplasty (traditional balloon angioplasty)
Number of subjects: 131
Study: 6395060

Group type: EXPERIMENTAL
Intervention: Silicone sponge soaked in antibiotic solution for at least 30 minutes prior to insertion
Number of subjects: 921

Group type: COMPARATOR
Intervention: Silicone sponge not soaked in antibiotic solution
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Use of multiple episcleral sponges
Number of subjects: 921
Study: 30468626

Group type: EXPERIMENTAL
Intervention: Fatigue of the first dorsal interosseous muscle (FDI) through two 100‐s index finger abduction maximum voluntary isometric contractions (MVICs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest for 5 minutes (control group)
Number of subjects: 15
Study: 27377790

Group type: EXPERIMENTAL
Intervention: Mobile-phone based home telehealth (MTH) intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 81
Study: 26703193

Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (IV TXA) 2 g
Number of subjects: 139

Group type: COMPARATOR
Intervention: Topical Tranexamic Acid (Topical TXA) 2 g
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (IV TXA)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Topical Tranexamic Acid (Topical TXA)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Intravenous and Topical Tranexamic Acid
Number of subjects: 139
Study: 25234206

Group type: EXPERIMENTAL
Intervention: Blood-pressure-lowering treatment (perindopril and indapamide)
Number of subjects: 8494

Group type: COMPARATOR
Intervention: Intensive glucose control
Number of subjects: 8494
Study: 22072050

Group type: EXPERIMENTAL
Intervention: Adjuvant radioactive iodine treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: No adjuvant radioactive iodine treatment
Number of subjects: 44
Study: 19284641

Group type: EXPERIMENTAL
Intervention: Hyperbaric treatment at 1.3 atm and 24% oxygen (treatment group, n = 33)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Slightly pressurized room air at 1.03 atm and 21% oxygen (control group, n = 29)
Number of subjects: 62
Study: 17542615

Group type: EXPERIMENTAL
Intervention: 100 g dose of steamed red cabbage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 300 g dose of steamed red cabbage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Anthocyanin metabolites
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nonacylated anthocyanins
Number of subjects: 12
Study: 16327112

Group type: EXPERIMENTAL
Intervention: HIV/AIDS and recidivism risk reduction intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study: 11356211

Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Er‐YAG laser treatment at 2Hz and 250mJ on dentin and 300mJ on enamel
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laser treatment followed by acid etching
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 18
Study: 9481883

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fenfluramine challenge test
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Side effects during challenge test
Number of subjects: 14
Study: 7884663

Group type: EXPERIMENTAL
Intervention: Cabergoline tablets (1‐mg single oral dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cabergoline solution (1‐mg single oral dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cabergoline tablets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cabergoline solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cabergoline tablets vs solution
Number of subjects: 12
Study: 2874821

Group type: EXPERIMENTAL
Intervention: Felodipine 5‐20 mg twice daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Hydralazine 25‐100 mg twice daily
Number of subjects: 101
Study: 29774642

Group type: EXPERIMENTAL
Intervention: Micropunch blepharopeeling (MBP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Blepharoplasty (BP)
Number of subjects: 22
Study: 26614823

Group type: EXPERIMENTAL
Intervention: Short-term oral ranolazine 500-1000 mg twice daily for 2 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 24783602

Group type: EXPERIMENTAL
Intervention: Counting group (patients instructed to count numbers backwards starting from 100 during propofol injection)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Non-counting group (patients injected with propofol without any instructions)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups (counting and non-counting)
Number of subjects: 91
Study: 24121454

Group type: EXPERIMENTAL
Intervention: Goshajinkigan (TJ-107) 7.5 g daily
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 21148246

Group type: EXPERIMENTAL
Intervention: Prescribed dietary phosphate restriction (≤ 870 mg, 871 to 999 mg, 1000 mg, 1001 to 2000 mg)
Number of subjects: 1751

Group type: COMPARATOR
Intervention: No phosphate restriction
Number of subjects: 1751
Study: 18679150

Group type: EXPERIMENTAL
Intervention: New formula for catheter insertion length (insertional length (cm) = (4 x birth weight [kg]) + 7)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: New formula for catheter insertion length
Number of subjects: 74

Group type: COMPARATOR
Intervention: Current practice using a nomogram derived from Dunn (control)
Number of subjects: 74
Study: 16531446

Group type: EXPERIMENTAL
Intervention: i.v. carperitide, 0.2 microg kg(‐1) min(‐1)
Number of subjects: 97

Group type: COMPARATOR
Intervention: i.v. normal saline (0.9% saline)
Number of subjects: 97
Study: 12682480

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11109471

Group type: EXPERIMENTAL
Intervention: Cesar therapy
Number of subjects: 222

Group type: COMPARATOR
Intervention: Standard treatment by general practitioner
Number of subjects: 222
Study: 9184781

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 1347812

Group type: EXPERIMENTAL
Intervention: Intrauterine device (IUD)
Number of subjects: 22908
Study: 7169652

Group type: EXPERIMENTAL
Intervention: Drained group
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-drained group
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 30732961

Group type: EXPERIMENTAL
Intervention: Bilateral level IB targeted (A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Bilateral IB spared (C)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Single level IB targeted (B)
Number of subjects: 86
Study: 29624254

Group type: EXPERIMENTAL
Intervention: Immediate release nimesulide formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference nimesulide formulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bioequivalence results
Number of subjects: 12
Study: 26245847

Group type: EXPERIMENTAL
Intervention: Lateral sitting training on a platform tilted 10° to the paretic side, 60 times/session, 6 sessions/week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy with no additional training
Number of subjects: 30
Study: 24673496

Group type: EXPERIMENTAL
Intervention: 1 mg luseogliflozin
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: 2.5 mg luseogliflozin
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: 5 mg luseogliflozin
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: 10 mg luseogliflozin
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 21566204

Group type: EXPERIMENTAL
Intervention: L‐NMMA (6.4 µmol/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: L‐NMMA in PGF(2α)‐preconstricted veins
Number of subjects: 10
Study: 19142567

Group type: COMPARATOR
Intervention: EPA&DHA (daily DHA/EPA capsules)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Fatty fish (150 g salmon, three times per week)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Lean fish (150 g cod, three times per week)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (no seafood)
Number of subjects: 324
Study: 17470016

Group type: EXPERIMENTAL
Intervention: Periodontal pathogens levels in preterm deliveries
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Maternal anti-Porphyromonas gingivalis IgG levels
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Levels of P. gingivalis, Tannerella forsythia, Prevotella intermedia, and Prevotella nigrescens postpartum
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Joint effects of red and orange microbial clusters
Number of subjects: 31
Study: 16873699

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (increasing physical activity, improving diet, decreasing body weight)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 522
Study: 12623959

Group type: EXPERIMENTAL
Intervention: felodipine (10 mg/d, n=14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: lercanidipine (10 mg/d, n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: acute drug administration
Number of subjects: 28
Study: 10519687

Group type: EXPERIMENTAL
Intervention: Brief advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provision of health education literature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of brief advice and health education literature
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8901795

Group type: EXPERIMENTAL
Intervention: 10.5 mg pure acetylsalicylic acid
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 9.1 mg salicylic acid
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Self-selected diets
Number of subjects: 17
Study: 1912752

Group type: EXPERIMENTAL
Intervention: Negotiable withdrawal schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed (non-negotiable) dose reduction schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 7120089

Group type: EXPERIMENTAL
Intervention: 8 mg perphenazine tablet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Two 8 mg perphenazine tablets
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 10 mg amitriptyline tablet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 10 mg amitriptyline tablet with 10 mg amitriptyline and 4 mg perphenazine combination tablet
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Two combination tablets (10 mg amitriptyline and 4 mg perphenazine each)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30520702

Group type: EXPERIMENTAL
Intervention: Videoconferencing (VC) assessment
Number of subjects: 19

Group type: COMPARATOR
Intervention: In-person (IP) assessment
Number of subjects: 19
Study: 28719594

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cyproheptadine
Number of subjects: 64
Study: 28695660

Group type: EXPERIMENTAL
Intervention: Menthacarin (2×1 capsule/day for 4 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (2×1 capsule/day for 4 weeks)
Number of subjects: 114
Study: 25544635

Group type: EXPERIMENTAL
Intervention: Treatment in both anterior and posterior regions
Number of subjects: 190

Group type: COMPARATOR
Intervention: Treatment in posterior region only
Number of subjects: 190
Study: 23588557

Group type: EXPERIMENTAL
Intervention: GBA1 mutation carriers
Number of subjects: 721
Study: 21041245

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 18154

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 18154
Study: 18492259

Group type: EXPERIMENTAL
Intervention: Ditrame-Plus (early HIV diagnosis and cotrimoxazole prophylaxis)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ditrame (standard care without cotrimoxazole prophylaxis)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Ditrame-Plus vs Ditrame
Number of subjects: 98

Group type: COMPARATOR
Intervention: Maternal death
Number of subjects: 98
Study: 16178052

Group type: EXPERIMENTAL
Intervention: Microwave-assisted silylation (MAS) followed by gas chromatography/mass spectrometry (GC/MS)
Number of subjects: 0
Study: 12695241

Group type: EXPERIMENTAL
Intervention: Latanoprost once a day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brimonidine twice a day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fixed combination of timolol and dorzolamide twice a day
Number of subjects: 20
Study: 10809861

Group type: EXPERIMENTAL
Intervention: Open wounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intact blisters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcipotriol-pretreated open wounds
Number of subjects: 0
Study: 8690826

Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (50-150 mg/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Imipramine (80-240 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 2070243

Group type: EXPERIMENTAL
Intervention: Graduated compression anti-embolism stocking
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no stocking)
Number of subjects: 40
Study: 6137978

Group type: COMPARATOR
Intervention: suxamethonium 1 mg X kg‐1 in a single bolus followed by an infusion (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: vecuronium 0.05 mg X kg‐1 (group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: vecuronium 0.06 mg X kg‐1 (group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: vecuronium 0.07 mg X kg‐1 (group D)
Number of subjects: 40
Study: 29973130

Group type: EXPERIMENTAL
Intervention: Video-assisted remote consultation (RMC)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Standard consultation (UNN)
Number of subjects: 389